These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 17488279)

  • 41. Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012).
    Roberts E; Guerrero M; Urbano M; Rosen H
    Expert Opin Ther Pat; 2013 Jul; 23(7):817-41. PubMed ID: 23541049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
    Clemens JJ; Davis MD; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes.
    Healy LM; Sheridan GK; Pritchard AJ; Rutkowska A; Mullershausen F; Dev KK
    Br J Pharmacol; 2013 Jul; 169(5):1114-29. PubMed ID: 23587004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
    Miron VE; Ludwin SK; Darlington PJ; Jarjour AA; Soliven B; Kennedy TE; Antel JP
    Am J Pathol; 2010 Jun; 176(6):2682-94. PubMed ID: 20413685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.
    Awad AS; Rouse MD; Khutsishvili K; Huang L; Bolton WK; Lynch KR; Okusa MD
    Kidney Int; 2011 May; 79(10):1090-8. PubMed ID: 21289599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.
    Janes K; Little JW; Li C; Bryant L; Chen C; Chen Z; Kamocki K; Doyle T; Snider A; Esposito E; Cuzzocrea S; Bieberich E; Obeid L; Petrache I; Nicol G; Neumann WL; Salvemini D
    J Biol Chem; 2014 Jul; 289(30):21082-97. PubMed ID: 24876379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy.
    Kim HJ; Jung CG; Dukala D; Bae H; Kakazu R; Wollmann R; Soliven B
    J Neuroimmunol; 2009 Sep; 214(1-2):93-100. PubMed ID: 19647880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K
    Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration.
    Reines I; Kietzmann M; Mischke R; Tschernig T; Lüth A; Kleuser B; Bäumer W
    J Invest Dermatol; 2009 Aug; 129(8):1954-62. PubMed ID: 19194476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Second generation S1P pathway modulators: research strategies and clinical developments.
    Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
    Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke.
    Liu J; Zhang C; Tao W; Liu M
    Int J Neurosci; 2013 Mar; 123(3):163-9. PubMed ID: 23167788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.
    Keller CD; Rivera Gil P; Tölle M; van der Giet M; Chun J; Radeke HH; Schäfer-Korting M; Kleuser B
    Am J Pathol; 2007 Jan; 170(1):281-92. PubMed ID: 17200201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
    Dudek SM; Camp SM; Chiang ET; Singleton PA; Usatyuk PV; Zhao Y; Natarajan V; Garcia JG
    Cell Signal; 2007 Aug; 19(8):1754-64. PubMed ID: 17475445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers.
    Cartwright TA; Campos CR; Cannon RE; Miller DS
    J Cereb Blood Flow Metab; 2013 Mar; 33(3):381-8. PubMed ID: 23168528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
    Yamamoto R; Okada Y; Hirose J; Koshika T; Kawato Y; Maeda M; Saito R; Hattori K; Harada H; Nagasaka Y; Morokata T
    PLoS One; 2014; 9(10):e110819. PubMed ID: 25347187
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
    Kihara A; Igarashi Y
    Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.
    Takabe K; Paugh SW; Milstien S; Spiegel S
    Pharmacol Rev; 2008 Jun; 60(2):181-95. PubMed ID: 18552276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
    Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
    Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
    Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
    Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
    Payne SG; Oskeritzian CA; Griffiths R; Subramanian P; Barbour SE; Chalfant CE; Milstien S; Spiegel S
    Blood; 2007 Feb; 109(3):1077-85. PubMed ID: 17008548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.